Table 1.
Generalized linear models for risk factors for CRBSI in patients due to suspected CRBSI
| Robust Std. Err | z-Value | RR (95% Conf. Interval) | P-value | |
|---|---|---|---|---|
| Admission | ||||
| APACHE1st quartile (2–14) (reference) | 1 | 1 | 1 | 1 |
| APACHE2nd quartile (15–18) | 0.301 | − 0.07 | 0.977(0.534–1.788) | 0.940 |
| APACHE3rd quartile (19–24) | 0.402 | 0.8 | 1.285(0.696–2.371) | 0.423 |
| APACHE4th quartile (25–46) | 0.541 | 1.71 | 1.714(0.924–3.182) | 0.088 |
| Comorbidities | ||||
| Acute Respiratory Distress Syndrome | 0.684 | 2.52 | 2.194(1.191–4.042) | 0.012 |
| Diabetes mellitus | 0.108 | − 3.4 | 0.354(0.194–0.644 | 0.001 |
| Kidney injury | 0.209 | − 1.74 | 0.421(0.159–1.114) | 0.082 |
| Severity of disease during suspected CRBSI | ||||
| SOFA1st quartile (1–7) (reference) | 1 | 1 | 1 | 1 |
| SOFA2nd quartile (8–9) | 0.196 | − 1.56 | 0.600(0.316–1.139) | 0.118 |
| SOFA3rd quartile (10–12) | 0.189 | − 1.66 | 0.584(0.310–1.100 | 0.096 |
| SOFA4th quartile (13–24) | 0.226 | − 1.29 | 0.628(0.310–1.273) | 0.197 |
| Central venous catheter | ||||
| Jugular (reference) | 1 | 1 | 1 | 1 |
| Subclavian | 0.053 | -5.65 | 0.167(0.090–0.311) | 0.000 |
| Femoral | 0.189 | − 1.23 | 0.725(0.434–1.209) | 0.218 |
| Catheter days (> 7) | 0.322 | 1.85 | 1.491(0.977–2.275) | 0.064 |
| General variables | ||||
| Temperature (> 38.3 °C) | 0.375 | 2.19 | 1.646(1.053–2.573) | 0.029 |
| Hemodynamic variables | ||||
| Arterial hypotension (MAP < 70 mmHg) | 0.549 | 2.57 | 2.016(1.182–3.437) | 0.010 |
| Vasoconstrictor Agents | 0.176 | − 1.87 | 0.553(0.297–1.030) | 0.062 |
| Inflammatory variables | ||||
| Leukocytes (WBC count > 12.000 μL-1) | 0.204 | − 0.33 | 0.930(0.605–1.429) | 0.740 |
| Leukopenia (WBC count < 4000 μL-1) | 3.681 | 0.88 | 2.977(0.264–33.596) | 0.378 |
| Plasma Procalcitonin (> 1 ng/ml) | 0.235 | 0.22 | 1.050(0.676–1.629) | 0.829 |
| Organ dysfunction variables | ||||
| Creatinine increase (> 133 μmol/L) | 0.088 | − 4.11 | 0.305(0.173–0.538) | 0.000 |
| Continuous renal replacement therapy | 1.098 | 4.54 | 3.761(2.122–6.666) | 0.000 |
| Hyperglycemia (plasma glucose > 10 mmol/L) | 0.390 | 2.46 | 1.737(1.119–2.697) | 0.014 |
| Glasgow Coma Scale (< 12) | 0.480 | 1.76 | 1.664(0.945–2.929) | 0.078 |
| Activated Partial Thromboplastin Time (> 60 secs) | 0.384 | 0.17 | 1.064(0.525–2.158) | 0.863 |
| International Normalized Ratio (> 1.5) | 0.237 | − 0.78 | 0.792(0.440–1.425) | 0.436 |
| Thrombocytopenia (platelet count < 100,000 μL−1) | 0.238 | − 0.49 | 0.875(0.513–1.492) | 0.623 |
| Tissue perfusion variables | ||||
| Hyperlactatemia (Lactic acid > 1 mmol/L) | 0.175 | − 1.37 | 0.713(0.440–1.155) | 0.169 |
Nonparametric ROC estimation to models: AUC 77.0% (95% CI 73.3%–80.7%)
APACHE Acute Physiology and Chronic Health Evaluation, CI confidence interval, CRBSI Catheter-related bloodstream infections, MAP mean arterial pressure, RR relative risk, SOFA Sequential Organ Failure Assessment, WBC white blood cell